Kashish Zehra Manjee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kashish Zehra Manjee has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Alishba Fatima
Dow University of Health Sciences, Karachi, Pakistan
2 shared publications - Danish Hassan
Dow Medical College, DUHS, Karachi, Pakistan
2 shared publications - Emad Uddin Sajid
Department of Medicine Dow University of Health Sciences Karachi Pakistan
2 shared publications - Muhammad Hasnain Azeem
Dow University of Health Sciences, Karachi, Pakistan
2 shared publications - Rida Shakeel
Department of Surgery, Dow Medical College, Karachi, Pakistan
2 shared publications - Syed Rayyan Ahmed
Department of Medicine Dow University of Health Sciences Karachi Pakistan
2 shared publications
Latest Publications
- Open Access
- 15 June 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (6) , e70369
Moderate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
Background: High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its comparative effectiveness after PCI remains uncertain. Methods: We performed a systematic review and meta‐analysis according to PRISMA guidelines. PubMed, Cochrane Library, and ClinicalTrials.gov were searched through September 2025 for studies enrolling adults undergoing PCI and comparing moderate‐intensity statin plus ezetimibe therapy with high‐intensity statin therapy. The primary outcome was major adverse cardiovascular events (MACE), defined as all‐cause mortality, myocardial infarction (MI), stroke, and revascularization. Secondary outcomes included individual cardiovascular endpoints and safety outcomes such as new‐onset diabetes and rhabdomyolysis. Random‐effects models were used to calculate pooled risk ratios (RRs). Results: Nine studies involving 179 621 patients were included, the majority being observational studies. No significant difference was observed in MACE between treatment strategies (RR 0.96, 95% CI 0.81–1.12). Modest reductions were observed in cardiovascular mortality (RR 0.83, 95% CI 0.71–0.98) and MI (RR 0.74, 95% CI 0.58–0.95), although findings were non‐robust with wide prediction intervals. Revascularization rates were similar between groups. Subgroup analyses suggested lower heterogeneity in intermediate follow‐up and non‐ACS populations. Conclusions: Moderate‐intensity statin plus ezetimibe therapy may provide cardiovascular outcomes comparable to high‐intensity statins after PCI. However, persistent heterogeneity limits certainty, and large randomized trials are needed to confirm long‐term efficacy and safety.
- 15 June 2026
- Published by Wiley in Clinical Cardiology
- Vol. 49 (6) , e70369
Open AccessModerate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After Percutaneous Coronary Intervention: A Systematic Review and Meta‐Analysis
Background: High‐intensity statins are standard therapy after percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), yet tolerability concerns and residual cardiovascular risk remain important challenges. Moderate‐intensity statin therapy combined with ezetimibe has emerged as a potential alternative, although its comparative effectiveness after PCI remains uncertain. Methods: We performed a systematic review and meta‐analysis according to PRISMA guidelines. PubMed, Cochrane Library, and ClinicalTrials.gov were searched through September 2025 for studies enrolling adults undergoing PCI and comparing moderate‐intensity statin plus ezetimibe therapy with high‐intensity statin therapy. The primary outcome was major adverse cardiovascular events (MACE), defined as all‐cause mortality, myocardial infarction (MI), stroke, and revascularization. Secondary outcomes included individual cardiovascular endpoints and safety outcomes such as new‐onset diabetes and rhabdomyolysis. Random‐effects models were used to calculate pooled risk ratios (RRs). Results: Nine studies involving 179 621 patients were included, the majority being observational studies. No significant difference was observed in MACE between treatment strategies (RR 0.96, 95% CI 0.81–1.12). Modest reductions were observed in cardiovascular mortality (RR 0.83, 95% CI 0.71–0.98) and MI (RR 0.74, 95% CI 0.58–0.95), although findings were non‐robust with wide prediction intervals. Revascularization rates were similar between groups. Subgroup analyses suggested lower heterogeneity in intermediate follow‐up and non‐ACS populations. Conclusions: Moderate‐intensity statin plus ezetimibe therapy may provide cardiovascular outcomes comparable to high‐intensity statins after PCI. However, persistent heterogeneity limits certainty, and large randomized trials are needed to confirm long‐term efficacy and safety.
- 8 May 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 111, 107222
Multimodal benefits of VR-based treadmill training in multiple sclerosis: A systematic review
- 8 May 2026
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 111, 107222
Multimodal benefits of VR-based treadmill training in multiple sclerosis: A systematic review
- 12 March 2024
- Published by Elsevier in Endocrine Practice
- Vol. 30 (5) , 481-489
Effect of Sodium-Glucose Cotransporter 2 Inhibitors on the 24-Hour Ambulatory Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension: An Updated Meta-Analysis
- 12 March 2024
- Published by Elsevier in Endocrine Practice
- Vol. 30 (5) , 481-489
Effect of Sodium-Glucose Cotransporter 2 Inhibitors on the 24-Hour Ambulatory Blood Pressure in Patients With Type 2 Diabetes Mellitus and Hypertension: An Updated Meta-Analysis
- 2 February 2024
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 34 (5) , 1334-1335
Letter to the Editor: Cardiovascular risk and the COVID-19 pandemic: A retrospective observational study in a population of healthcare professionals
- 2 February 2024
- Published by Elsevier in Nutrition, Metabolism and Cardiovascular Diseases
- Vol. 34 (5) , 1334-1335
Letter to the Editor: Cardiovascular risk and the COVID-19 pandemic: A retrospective observational study in a population of healthcare professionals
- Open Access
- 1 November 2023
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 43 (5) , 299-300
High prevalence of cardiovascular disease and risk factors among type 2 diabetes patients followed in a hospital setting in Portugal
- 1 November 2023
- Published by Elsevier in Revista Portuguesa de Cardiologia
- Vol. 43 (5) , 299-300
Open AccessHigh prevalence of cardiovascular disease and risk factors among type 2 diabetes patients followed in a hospital setting in Portugal